These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 7679429)

  • 1. Modulation of human basophil histamine release by insulin-like growth factors.
    Hirai K; Miyamasu M; Yamaguchi M; Nakajima K; Ohtoshi T; Koshino T; Takaishi T; Morita Y; Ito K
    J Immunol; 1993 Feb; 150(4):1503-8. PubMed ID: 7679429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of human basophil sulfidopeptide leukotriene release: releasability defined as the ability of the basophil to respond to dimeric cross-links.
    MacGlashan DW; Peters SP; Warner J; Lichtenstein LM
    J Immunol; 1986 Mar; 136(6):2231-9. PubMed ID: 2419427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of basophils in allergic disease.
    Knol EF; Mul FP; Lie WJ; Verhoeven AJ; Roos D
    Eur Respir J Suppl; 1996 Aug; 22():126s-131s. PubMed ID: 8871057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of basophils by stem cell factor: comparison with insulin-like growth factor-I.
    Koketsu R; Suzukawa M; Kawakami A; Komiya A; Ra C; Yamamoto K; Yamaguchi M
    J Investig Allergol Clin Immunol; 2008; 18(4):293-9. PubMed ID: 18714538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the human basophil response to cytokines, growth factors, and histamine releasing factors of the intercrine/chemokine family.
    Kuna P; Reddigari SR; Schall TJ; Rucinski D; Sadick M; Kaplan AP
    J Immunol; 1993 Mar; 150(5):1932-43. PubMed ID: 7679699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of IgE-dependent histamine releasing factors: heterogeneity of IgE.
    MacDonald SM; Lichtenstein LM; Proud D; Plaut M; Naclerio RM; MacGlashan DW; Kagey-Sobotka A
    J Immunol; 1987 Jul; 139(2):506-12. PubMed ID: 2439589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors.
    Reeve JG; Morgan J; Schwander J; Bleehen NM
    Cancer Res; 1993 Oct; 53(19):4680-5. PubMed ID: 7691401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble insulin-like growth factor II/mannose 6-phosphate receptor inhibits DNA synthesis in insulin-like growth factor II sensitive cells.
    Scott CD; Weiss J
    J Cell Physiol; 2000 Jan; 182(1):62-8. PubMed ID: 10567917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basophil releasability in the newborn: factors limiting immunoglobulin E-mediated histamine release.
    Mendoza GR; Minagawa K; Orner FB; Stiehm ER
    Pediatrics; 1982 Feb; 69(2):188-92. PubMed ID: 6173838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IFN-alpha inhibits IL-3 priming of human basophil cytokine secretion but not leukotriene C4 and histamine release.
    Chen YH; Bieneman AP; Creticos PS; Chichester KL; Schroeder JT
    J Allergy Clin Immunol; 2003 Nov; 112(5):944-50. PubMed ID: 14610485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The degradation product of the C5a anaphylatoxin C5adesarg retains basophil-activating properties.
    Bürgi B; Brunner T; Dahinden CA
    Eur J Immunol; 1994 Jul; 24(7):1583-9. PubMed ID: 7517876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor-II stimulates steroidogenesis in cultured bovine thecal cells.
    Spicer LJ; Voge JL; Allen DT
    Mol Cell Endocrinol; 2004 Nov; 227(1-2):1-7. PubMed ID: 15501579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of basophil histamine release by anti-inflammatory steroids. II. Studies on the mechanism of action.
    Schleimer RP; MacGlashan DW; Gillespie E; Lichtenstein LM
    J Immunol; 1982 Oct; 129(4):1632-6. PubMed ID: 6180017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement-induced histamine release from human basophils. II. Mechanism of the histamine release reaction.
    Siraganian RP; Hook WA
    J Immunol; 1976 Mar; 116(3):639-46. PubMed ID: 56398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IGF-II is more active than IGF-I in stimulating L6A1 myogenesis: greater mitogenic actions of IGF-I delay differentiation.
    Ewton DZ; Roof SL; Magri KA; McWade FJ; Florini JR
    J Cell Physiol; 1994 Nov; 161(2):277-84. PubMed ID: 7962112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of constitutively activated and insulin-like growth factor-stimulated ERK1/2 signaling in human hepatoma cell proliferation and apoptosis: evidence for heterogeneity of tumor cell lines.
    Alexia C; Lasfer M; Groyer A
    Ann N Y Acad Sci; 2004 Dec; 1030():219-29. PubMed ID: 15659801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-I and- II in combination inhibit the release of growth hormone-releasing hormone from the rat hypothalamus in vitro.
    Korbonits M; Little JA; Camacho-Hübner C; Trainer PJ; Besser GM; Grossman AB
    Growth Regul; 1996 Jun; 6(2):110-20. PubMed ID: 8781987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative studies of the granulopoietic enhancing effects of biosynthetic human insulin-like growth factors I and II.
    Merchav S; Lake M; Skottner A
    J Cell Physiol; 1993 Oct; 157(1):178-83. PubMed ID: 8408236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of selective basophil chemoattractants in human nasal polyps as insulin-like growth factor-1 and insulin-like growth factor-2.
    Hartnell A; Heinemann A; Conroy DM; Wait R; Sturm GJ; Caversaccio M; Jose PJ; Williams TJ
    J Immunol; 2004 Nov; 173(10):6448-57. PubMed ID: 15528386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of insulin-like growth factor binding protein complexes on human fibroblast growth.
    Tesch GH; Cornell HJ; Herington AC; Oakes S
    Growth Regul; 1993 Jun; 3(2):151-9. PubMed ID: 7687915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.